Review
Nature Reviews Drug Discovery 2, 803-811 (October 2003) | doi:10.1038/nrd1199
HIF-1 as a target for drug development
Amato Giaccia1, Bronwyn G. Siim2 & Randall S. Johnson3 About the authors
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
- View At a Glance
Author affiliations
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305-5468, USA.
- Auckland Cancer Society Research Centre, University of Auckland, Private Bag 92019, Auckland, NZ.
- Division of Biological Sciences, University of California San Diego, 9500 Gilman Drive, MC-0366, La Jolla, California 92093-0366, USA.
Correspondence to: Randall S. Johnson3 Email: rjohnson@biomail.ucsd.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
induces cell cycle arrest by functionally counteracting Myc
